NCT00001271View on ClinicalTrials.gov

A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

July 31, 1991

Study Completion Date

April 30, 2001

Conditions

B Cell Lymphoma

Interventions

DRUG

IgG-RFB4-SMPT-dgA

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH